Exenatide vs Liraglutide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

GLP-1 Receptor Agonist

Exenatide

Brand: Byetta

First FDA approval: 2014-12-10

GLP-1 Receptor Agonist

Liraglutide

Brand: Saxenda

First FDA approval: 2010-01-25

Lowest NADACAcquisition cost floor across all NDCs

$299.50Per unit

$39.43Per unit

Average NADACAcross all dosage forms and strengths

$299.50Up to $299.50

$55.46Up to $87.86

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

68 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$18.7MFull year

$383.1MFull year

Part D claims (CY24)Total fills, all strengths

14K5K beneficiaries

457K170K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$1,311Per claim, all NDCs

$839Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

48Minimal friction

97Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Active shortageSee drug profile

Generic availableFDA Orange Book

NoBrand-only

Yes6 manufacturers